Advertisement
Australia markets close in 1 hour 30 minutes
  • ALL ORDS

    8,025.20
    +13.10 (+0.16%)
     
  • ASX 200

    7,784.20
    +14.80 (+0.19%)
     
  • AUD/USD

    0.6668
    +0.0010 (+0.15%)
     
  • OIL

    82.34
    +0.17 (+0.21%)
     
  • GOLD

    2,374.70
    +5.70 (+0.24%)
     
  • Bitcoin AUD

    96,909.28
    -907.94 (-0.93%)
     
  • CMC Crypto 200

    1,353.93
    -28.74 (-2.08%)
     
  • AUD/EUR

    0.6220
    +0.0003 (+0.06%)
     
  • AUD/NZD

    1.0885
    +0.0012 (+0.11%)
     
  • NZX 50

    11,761.33
    -10.48 (-0.09%)
     
  • NASDAQ

    19,752.30
    -156.56 (-0.79%)
     
  • FTSE

    8,272.46
    +67.35 (+0.82%)
     
  • Dow Jones

    39,134.76
    +299.90 (+0.77%)
     
  • DAX

    18,254.18
    +186.27 (+1.03%)
     
  • Hang Seng

    18,021.56
    -313.76 (-1.71%)
     
  • NIKKEI 225

    38,633.12
    +0.10 (+0.00%)
     

Why Shares of Ocular Therapeutix Jumped This Week

Why Shares of Ocular Therapeutix Jumped This Week

Shares of Ocular Therapeutix (NASDAQ: OCUL) were up by 49.6% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company specializes in finding therapies to treat diseases and conditions of the eye. The healthcare company, on Feb. 11, announced preliminary 10-month data on its phase 1 trial of OTX-TKI, an axitinib (a small molecule, multitarget, tyrosine kinase inhibitor) intravitreal (inside the eye) hydrogel implant to treat age-related macular degeneration (AMD), diabetic retinopathy and other diseases of the retina.